Vertex Total Assets from 2010 to 2024

VRTX Stock

USD 468.13 3.57 0.77%

Vertex Pharmaceuticals Total Assets yearly trend continues to be fairly stable with very little volatility. Total Assets are likely to outpace its year average in 2024. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

1990-12-31

Previous Quarter

20.1 B

Current Value

22.2 B

Quarterly Volatility

5.6 B

Oil Shock

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Vertex Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vertex Pharmaceuticals' main balance sheet or income statement drivers, such as Total Revenue of 10.4 B, Gross Profit of 9 B or Other Operating Expenses of 6.3 B, as well as many indicators such as Price To Sales Ratio of 10.09, Dividend Yield of 0.0 or PTB Ratio of 7.46. Vertex financial statements analysis is a perfect complement when working with Vertex Pharmaceuticals Valuation or Volatility modules.

Check out the analysis of Vertex Pharmaceuticals Correlation against competitors.

For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.

Latest Vertex Pharmaceuticals' Total Assets Growth Pattern

Below is the plot of the Total Assets of Vertex Pharmaceuticals over the last few years. Total assets refers to the total amount of Vertex Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Vertex Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Vertex Pharmaceuticals' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vertex Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 22.73 B

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Total Assets

Timeline

Vertex Total Assets Regression Statistics

	Arithmetic Mean	8,204,096,200
	Geometric Mean	3,859,234,187
	Coefficient Of Variation	96.82
	Mean Deviation	6,536,800,773
	Median	3,546,014,000
	Standard Deviation	7,943,400,577
	Sample Variance	63097612.7T
	Range	23.9B
	R-Value	0.91
	Mean Square Error	11123406.5T
	R-Squared	0.84
	Slope	1,624,326,557
	Total Sum of Squares	883366578.3T

Vertex Total Assets History

	2024	23.9 B
	2023	22.7 B
	2022	18.2 B
	2021	13.4 B
	2020	11.8 B
	2019	8.3 B
	2018	6.2 B

Other Fundumenentals of Vertex Pharmaceuticals

Intangibles To Total Assets

Vertex Pharmaceuticals Total Assets component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Total Liab	Total Current Assets	Short Term Debt	Accounts Payable	Net Receivables	Common Stock	Long Term Debt	Short Term Investments	Property Plant Equipment	Current Deferred Revenue	Good Will	Intangible Assets	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Short Long Term Debt	Long Term Investments	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		1.0	-0.98	0.94	0.99	1.0	-0.07	0.98	0.99	0.37	0.04	0.23	0.93	0.2	0.83	0.44	0.99	0.08	0.66	-0.55	0.78	0.79	0.93	0.92	0.78
Total Stockholder Equity	1.0		-0.98	0.95	0.98	1.0	-0.08	0.97	0.99	0.35	0.01	0.22	0.92	0.21	0.84	0.44	1.0	0.06	0.66	-0.56	0.79	0.79	0.94	0.92	0.78
Net Debt	-0.98	-0.98		-0.94	-0.96	-0.99	0.1	-0.95	-0.99	-0.34	0.0	-0.13	-0.89	-0.24	-0.84	-0.45	-0.99	0.02	-0.66	0.55	-0.79	-0.68	-0.96	-0.97	-0.69
Retained Earnings	0.94	0.95	-0.94		0.89	0.94	-0.07	0.93	0.93	0.07	-0.14	0.12	0.79	0.1	0.76	0.58	0.94	-0.07	0.44	-0.35	0.63	0.81	0.9	0.89	0.79
Total Liab	0.99	0.98	-0.96	0.89		0.99	-0.02	0.98	0.98	0.47	0.12	0.27	0.94	0.19	0.81	0.43	0.97	0.17	0.68	-0.55	0.78	0.78	0.91	0.9	0.76
Total Current Assets	1.0	1.0	-0.99	0.94	0.99		-0.08	0.98	0.99	0.37	0.03	0.21	0.93	0.21	0.83	0.44	1.0	0.07	0.65	-0.56	0.78	0.76	0.94	0.94	0.75
Short Term Debt	-0.07	-0.08	0.1	-0.07	-0.02	-0.08		0.02	-0.07	0.02	-0.13	-0.3	-0.03	-0.15	-0.28	0.12	-0.1	-0.05	-0.2	0.24	-0.17	0.09	-0.11	-0.11	0.03
Accounts Payable	0.98	0.97	-0.95	0.93	0.98	0.98	0.02		0.96	0.38	0.1	0.23	0.92	0.18	0.72	0.47	0.96	0.18	0.57	-0.46	0.69	0.82	0.9	0.89	0.8
Net Receivables	0.99	0.99	-0.99	0.93	0.98	0.99	-0.07	0.96		0.37	0.02	0.18	0.91	0.22	0.86	0.45	0.99	0.03	0.67	-0.55	0.8	0.72	0.94	0.94	0.71
Common Stock	0.37	0.35	-0.34	0.07	0.47	0.37	0.02	0.38	0.37		0.6	0.51	0.56	0.28	0.34	-0.1	0.36	0.42	0.72	-0.61	0.48	0.13	0.4	0.38	0.23
Long Term Debt	0.04	0.01	0.0	-0.14	0.12	0.03	-0.13	0.1	0.02	0.6		0.41	0.21	-0.05	0.02	-0.1	0.01	0.87	0.31	-0.23	0.0	-0.04	0.11	0.09	0.06
Short Term Investments	0.23	0.22	-0.13	0.12	0.27	0.21	-0.3	0.23	0.18	0.51	0.41		0.28	-0.06	0.29	0.02	0.21	0.34	0.21	-0.25	0.09	0.25	0.22	0.17	0.27
Property Plant Equipment	0.93	0.92	-0.89	0.79	0.94	0.93	-0.03	0.92	0.91	0.56	0.21	0.28		0.2	0.73	0.16	0.93	0.29	0.77	-0.75	0.79	0.73	0.84	0.83	0.72
Current Deferred Revenue	0.2	0.21	-0.24	0.1	0.19	0.21	-0.15	0.18	0.22	0.28	-0.05	-0.06	0.2		0.06	-0.2	0.25	-0.14	0.43	-0.34	0.55	0.03	0.21	0.18	0.04
Good Will	0.83	0.84	-0.84	0.76	0.81	0.83	-0.28	0.72	0.86	0.34	0.02	0.29	0.73	0.06		0.4	0.83	-0.07	0.68	-0.55	0.76	0.49	0.83	0.81	0.5
Intangible Assets	0.44	0.44	-0.45	0.58	0.43	0.44	0.12	0.47	0.45	-0.1	-0.1	0.02	0.16	-0.2	0.4		0.4	-0.23	-0.06	0.41	0.07	0.41	0.54	0.54	0.5
Net Tangible Assets	0.99	1.0	-0.99	0.94	0.97	1.0	-0.1	0.96	0.99	0.36	0.01	0.21	0.93	0.25	0.83	0.4		0.05	0.68	-0.59	0.8	0.76	0.94	0.93	0.75
Long Term Debt Total	0.08	0.06	0.02	-0.07	0.17	0.07	-0.05	0.18	0.03	0.42	0.87	0.34	0.29	-0.14	-0.07	-0.23	0.05		0.18	-0.22	-0.05	0.19	-0.01	-0.02	0.16
Capital Surpluse	0.66	0.66	-0.66	0.44	0.68	0.65	-0.2	0.57	0.67	0.72	0.31	0.21	0.77	0.43	0.68	-0.06	0.68	0.18		-0.86	0.88	0.37	0.68	0.64	0.47
Deferred Long Term Liab	-0.55	-0.56	0.55	-0.35	-0.55	-0.56	0.24	-0.46	-0.55	-0.61	-0.23	-0.25	-0.75	-0.34	-0.55	0.41	-0.59	-0.22	-0.86		-0.73	-0.28	-0.52	-0.5	-0.3
Short Long Term Debt	0.78	0.79	-0.79	0.63	0.78	0.78	-0.17	0.69	0.8	0.48	0.0	0.09	0.79	0.55	0.76	0.07	0.8	-0.05	0.88	-0.73		0.48	0.73	0.7	0.49
Long Term Investments	0.79	0.79	-0.68	0.81	0.78	0.76	0.09	0.82	0.72	0.13	-0.04	0.25	0.73	0.03	0.49	0.41	0.76	0.19	0.37	-0.28	0.48		0.65	0.59	0.95
Net Invested Capital	0.93	0.94	-0.96	0.9	0.91	0.94	-0.11	0.9	0.94	0.4	0.11	0.22	0.84	0.21	0.83	0.54	0.94	-0.01	0.68	-0.52	0.73	0.65		0.99	0.73
Net Working Capital	0.92	0.92	-0.97	0.89	0.9	0.94	-0.11	0.89	0.94	0.38	0.09	0.17	0.83	0.18	0.81	0.54	0.93	-0.02	0.64	-0.5	0.7	0.59	0.99		0.66
Capital Stock	0.78	0.78	-0.69	0.79	0.76	0.75	0.03	0.8	0.71	0.23	0.06	0.27	0.72	0.04	0.5	0.5	0.75	0.16	0.47	-0.3	0.49	0.95	0.73	0.66

Click cells to compare fundamentals

About Vertex Pharmaceuticals Financial Statements

Vertex Pharmaceuticals investors use historical fundamental indicators, such as Vertex Pharmaceuticals' Total Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Vertex Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Total Assets	22.7 B	23.9 B
Intangibles To Total Assets	0.08	0.15

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

TITAN	Titan Company Limited
U	Unity Software
PAYC	Paycom Soft

Additional Tools for Vertex Stock Analysis

When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC